Germany Focuses on Private Sector Treatment Access Demand for obesity GLP-1 treatment in Germany is projected to grow at a CAGR of 19.6%, constrained by statutory health insurance exclusions for anti-obesity medications that limit public reimbursement
Advise patients of the importance of seeking medical advice promptly during periods of stress such as fever, trauma, infection, or surgery as medication requirements may change
[ 5 ] At 12 months, Noom members were estimated to regain 21.2% of lost weight, compared with 61.4% in published benchmarks
Some people come weekly during illness, others schedule monthly maintenance treatments, and athletes may visit before and after competitions
Continuing these activities after receiving the letter significantly increases your legal exposure
Unfortunately, these medications are currently quite expensive, and insurance will not cover their use for AUD, Schacht says